Endeavor is a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis.
Endeavor BioMedicines is focused on precision treatments for terminal conditions, including cancer and fibrosis.
Endeavor BioMedicines was co-founded in 2018 by John Hood and Miguel De Los Rios. The company is headquartered in San Diego, California.
Endeavor combines advancements in technology with an evolving understanding of terminal diseases to develop best-in-class medicines with the potential to reverse the most severe health conditions.
Endeavor's lead program, ENV-101, is a Hedgehog signaling inhibitor with proven clinical activity that we are investigating in multiple cancers and in idiopathic pulmonary fibrosis.
Endeavor is backed by Ally Bridge Group, Omega Funds, Avidity Partners, Longitude Capital, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, and others. The company raised $101M in Series B round on Feb 08, 2022. This brings Endeavor's total funding to $163M to date.